A High-dose Bortezomib Neuropathy with Sensory Ataxia and Myelin Involvement

Overview

Journal J Neurol Sci

Publisher Elsevier

Specialty Neurology

Date 2007 Jul 7

PMID 17612569

Citations 8

Authors

Massimiliano Filosto

Giuseppe Rossi

Anna Maria Pelizzari

Serena Buzio

Marta Tentorio

Laura Broglio

Michelangelo Mancuso

Marianna Rinaldi

Mauro Scarpelli

Alessandro Padovani

Affiliations

Soon will be listed here.

Abstract

Bortezomib, a proteasome inhibitor used in the treatment of multiple myeloma, is known to induce an axonal, dose-dependent neuropathy clinically characterized by pain, paresthesias, burning dysesthesias and numbness. In this study, we describe a patient treated with high-dose bortezomib whose main clinical feature was severe sensory ataxia. Electrodiagnostic studies showed, other than axonal changes, myelin involvement.

Citing Articles

An In Vitro Assessment Method for Chemotherapy-Induced Peripheral Neurotoxicity Caused by Anti-Cancer Drugs Based on Electrical Measurement of Impedance Value and Spontaneous Activity.

Han X, Matsuda N, Ishibashi Y, Shibata M, Suzuki I Pharmaceutics. 2023; 15(12).

PMID: 38140128 PMC: 10748260. DOI: 10.3390/pharmaceutics15122788.

The Effect of Schwann Cells/Schwann Cell-Like Cells on Cell Therapy for Peripheral Neuropathy.

Wang Q, Chen F, Ling Z, Su W, Zhao Y, Chen G Front Cell Neurosci. 2022; 16:836931.

PMID: 35350167 PMC: 8957843. DOI: 10.3389/fncel.2022.836931.

Non-Hematologic Toxicity of Bortezomib in Multiple Myeloma: The Neuromuscular and Cardiovascular Adverse Effects.

Pancheri E, Guglielmi V, Wilczynski G, Malatesta M, Tonin P, Tomelleri G Cancers (Basel). 2020; 12(9).

PMID: 32906684 PMC: 7563977. DOI: 10.3390/cancers12092540.

Pain Management in Patients with Multiple Myeloma: An Update.

Coluzzi F, Rolke R, Mercadante S Cancers (Basel). 2019; 11(12).

PMID: 31861097 PMC: 6966684. DOI: 10.3390/cancers11122037.

Prevention of chemotherapy-induced peripheral neuropathy: A review of recent findings.

Ibrahim E, Ehrlich B Crit Rev Oncol Hematol. 2019; 145:102831.

PMID: 31783290 PMC: 6982645. DOI: 10.1016/j.critrevonc.2019.102831.